+198.4%
SPYM vs MRNA
+786.4%
-588.0%
-33.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.5% | -2.2% | -1.4% | -3.5% |
| 7D | -8.4% | -12.7% | +4.3% | -8.0% |
| 30D | -10.7% | -20.7% | +10.0% | -10.1% |
| 3M | -9.2% | +46.3% | -55.5% | -10.6% |
| 6M | -6.4% | +305.2% | -311.6% | -14.1% |
| YTD | +2.1% | +561.2% | -559.1% | -9.4% |
| 1Y | +7.0% | +772.1% | -765.1% | -6.6% |
| 3Y | +58.0% | +147.0% | -89.0% | +44.4% |
| 5Y | +57.9% | -26.1% | +84.0% | +48.7% |
| All | +198.4% | +786.4% | -588.0% | +157.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling